Literature DB >> 8513457

The clinical relevance of Enterobacter infections.

D M Shlaes1.   

Abstract

An 18-month prospective study of Enterobacter bacteremia was conducted in 129 patients. The results indicated that (1) emergence of resistance was more frequent during treatment with third-generation cephalosporins than with other antibiotics; (2) the addition of an aminoglycoside to the cephalosporin did not prevent emergence of resistance; (3) previous treatment with cephalosporins was associated with bacteremia caused by multiresistant Enterobacter species; and (4) infection with multiresistant Enterobacter species was associated with a higher mortality than infection with susceptible strains. It is concluded that avoidance of third-generation cephalosporins for surgical prophylaxis and therapy in patients in whom Enterobacter infections are suspected or proven should lower the prevalence of Enterobacter bacteremias and mortality and prevent the emergence of multiresistance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513457

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

1.  A nosocomial outbreak due to Enterobacter cloacae strains with the E. hormaechei genotype in patients treated with fluoroquinolones.

Authors:  A Davin-Regli; C Bosi; R Charrel; E Ageron; L Papazian; P A Grimont; A Cremieux; C Bollet
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

2.  Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units.

Authors:  A Davin-Regli; D Monnet; P Saux; C Bosi; R Charrel; A Barthelemy; C Bollet
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

3.  An Enterobacter plasmid as a new genetic background for the transposon Tn1331.

Authors:  Mohammad R Alavi; Vlado Antonic; Adrien Ravizee; Peter J Weina; Mina Izadjoo; Alexander Stojadinovic
Journal:  Infect Drug Resist       Date:  2011-11-28       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.